Abstract
ObjectiveDoes quantitative analysis of the gadoxetate hepatocyte phase homogeneity, measuring percent standard deviation of hepatocyte phase (SDHP) and liver-to-kidney enhancement ratio (LiKER) detect early hepatic fibrosis? Materials and methodsRetrospective review of gadoxetate liver MRI plus biopsy-proven fibrosis within 6 months included 31 reversible hepatic fibrosis, 33 irreversible hepatic fibrosis, and 15 donors. Parenchymal and vascular SDHP and LiKER were measured on the 20-min hepatocyte phase using region of interest. ResultsParenchymal SDHP, vascular SDHP and LiKER measurements differentiate early hepatic fibrosis from controls (P<.01). ConclusionQuantitative analysis of gadoxetate hepatocyte phase homogeneity using SDHP and LiKER is a promising imaging biomarker for diagnosis of early liver fibrosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
